Monoclonal antibodies (mAbs) generated against α-2,3-linked sialic acid—a terminal N-glycan structure that has been identified on the PSA of patients with prostate cancer—have been used to quantify PSA10. This evidence concerns the gene KLK3 and Familial prostate cancer.